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Abstract  
Background: Congestion due to cardiac dysfunction is an important cause of heart failure (HF) 
symptoms and signs. Diuretics are the mainstay of treatment for congestion but concerns exist 
that they induce neuro-endocrine activation which may adversely affect prognosis.  
Aim: to explore whether the relationship between loop diuretic use and outcome is explained 
by underlying congestion amongst patients referred with suspected heart failure.   
Results: Of 1190 patients, 712 had a left ventricular ejection fraction (LVEF) <50%, 267 had 
only raised plasma NTproBNP (>400 ng/L) and 211 (18%) had neither; respectively, 72%, 68% 
and 37% of these groups were treated with loop diuretics including 28%, 29% and 10% in doses 
>=80mg/day. 
Compared to patients with cardiac dysfunction (either LVEF <50% or NT-proBNP >400ng/L) 
but not taking a loop diuretic, those taking a loop diuretic were older, had more evidence of 
congestion, lower LVEF, worse renal function, more anaemia and hyponatraemia. 
 
During a median follow-up of 934 (IQR: 513 – 1425) days, 450 patients were hospitalized for 
HF or died. Patients prescribed loop diuretics had a worse prognosis. However, in multi-
variable models, clinical, echocardiographic (inferior vena cava diameter), and biochemical 
(NTproBNP) measures of congestion were strongly associated with an adverse outcome but 
neither the use nor dose of loop diuretics. 
 
Conclusions: Prescription of loop diuretics identifies patients with more advanced features of 
heart failure and congestion. This association appears to account for the worse prognosis of 
patients treated with loop diuretics.  
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Introduction 
Amongst patients with heart failure, clinical (1, 2), echocardiographic (3-5), or biochemical (6-
8) evidence of congestion is associated with an increased rate of hospitalization and higher 
mortality. Diuretics, especially high-ceiling diuretics acting on the Loop of Henle, are the 
mainstay of treatment for congestion in order to relieve symptoms and signs, but may activate 
the renin-angiotensin-aldosterone and sympathetic nervous systems which is thought to 
contribute to the progression and adverse outcome of heart failure (9, 10).   
 
However, there is a remarkable paucity of data on how diuretics should be best used to improve 
outcomes in heart failure. Conventional clinical practice is to use sufficient doses to relieve 
symptoms and signs of congestion. Once started, there is often no attempt to stop diuretic 
therapy to find out whether chronic daily dosing is required and there is often reluctance to 
prescribe higher doses to patients with more advanced heart failure (11). No randomised study 
has ever demonstrated whether loop diuretics alter mortality in patients with chronic heart 
failure.  There is a strong association between the use of loop diuretic agents, especially in 
higher doses, and worse outcome (12, 13) but this may merely a barometer of congestion (14). 
The observed relationship between diuretic dose, severity of congestion and outcome deserves 
further investigation.   
 
Accordingly, we compared the relation between diuretic dose, congestion and outcome in 
patients with chronic heart failure (either with reduced or normal left ventricular ejection 
fraction), using three different methods for assessing congestion: a clinical congestion scale; a 
biochemical measurement (natriuretic peptides); and imaging (inferior vena cava diameter). 
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Methods 
Study Population 
Out-patients attending a community heart failure clinic with suspected or confirmed heart 
failure (HF) between November 2008 and May 2013 were enrolled and followed for at least 
nine months.  HF was defined as symptoms or signs of HF, supported by objective evidence of 
cardiac dysfunction: either a left ventricular ejection fraction (LVEF) <50% at 
echocardiography or raised plasma concentration of amino-terminal pro-brain natriuretic 
peptide (NT-proBNP) (>400 ng/l) (15). Patients were grouped as: those without substantial 
evidence of cardiac dysfunction (NTproBNP <400 ng/l and LVEF >50%) and, for patients with 
HF, by the daily dose of loop diuretics taken (none, Furosemide or equivalent < 40 mg/day, >40 
to 80 mg/day, > 80 mg/day). Those without objective evidence of cardiac dysfunction were 
further divided in patients with NT-proBNP <125 ng/l or NTproBNP between 125 ng/l and 400 
ng/l (16).   
 
Patients provided a detailed clinical history and had blood tests (including haematology, 
biochemistry profile and NT-proBNP), ECGs and echocardiograms on the same day. Ischaemic 
heart disease was defined as a previous history of myocardial infarction or angiographic 
evidence of significant coronary artery disease (>70% on epicardial vessels). Hypertension and 
diabetes were based on prior medical history from medical records obtained from the general 
practitioner or from information collected at clinical visits. Patients in atrial fibrillation or atrial 
flutter were grouped as “AF”.  
A congestion score was constructed, based on lung auscultation (normal, presence of basal, 
mid-zone or diffuse crepitations), JVP (not visible, raised 1-4 cm, raised to earlobe), peripheral 
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oedema (none, ankles, below or above knees) and liver examination (not palpable, palpable) 
with one point attributed for each degree of severity and a total possible score of nine (17). 
Data regarding hospitalizations and death were collected from the hospital’s electronic systems, 
the only one in the region offering acute medical services, supplemented by information from 
patients and their family doctors. Outcome was censored at the point of last medical contact in 
either primary or secondary care. Vital status was confirmed from national records. The primary 
outcome was a composite of admission for worsening HF or death from all causes. Admission 
for HF was defined as an admission for worsening of relevant symptoms resulting in substantial 
intensification of treatment for HF.  
 
The study conforms to the principles outlined in the Declaration of Helsinki and was approved 
by relevant ethical bodies. All subjects gave their written informed consent for their data to be 
used at their first clinical visit. 
 
Echocardiographic measurements 
Echocardiography was performed by experienced operators using a Vivid Five, Seven or Nine 
(GE Health Care, UK) system. Echocardiograms were reviewed by a single operator (PP) 
blinded to other patient details. LVEF was measured using Simpson’s biplane method. LA 
volume was indexed to body surface area (LAVI). Tricuspid annular plane systolic excursion 
(TAPSE) was used to assess RV systolic function. The trans-tricuspid systolic gradient was also 
measured when a suitable Doppler signal was available. With the patient supine, the maximum 
IVC diameter during the respiratory cycle was measured approximately three centimetres 
before merger with the right atrium.  
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Congestion 
We used three indices as measures of congestion. 
a. Clinical congestion score: Patients with a score of 1 or 2 out of a possible score of nine 
were defined as mildly congested; those with a score of 3 or more were defined as 
severely congested (17). 
b. Echocardiographic congestion: we used the size of the inferior vena cava to define three 
groups. Patients with an IVC <16 mm were not considered to be congested, those with 
an IVC 17-20 mm were defined as mildly congested, those with an IVC >21 mm were 
considered severely congested. (18) 
c. Biochemical congestion: we used NTproBNP to define three groups, based on current 
and previous guidelines (Not congested: NTproBNP<125 ng/l; Possible congestion: 
125-400 ng/l; congestion: NTproBNP > 400 ng/l; (15, 16)), or by classifying patients 
according to NTproBNP terciles (Tercile 1, less congested; Tercile 2: intermediate 
congestion; Tercile 3: most congested).  
 
Statistical methods 
Categorical data are presented as number and percentages; normally distributed 
continuous data as mean + standard deviation (SD); non-normally distributed variables 
as median and interquartile range (IQR).  
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Student T-Test or Mann Whitney U test, and one-way analysis of variance and Kruskal-
Wallis tests were used to compare continuous variables between groups. Chi-squared 
tests were for categorical variables. Associations between variables and prognosis were 
assessed using Cox proportional hazards models.  Multivariable models were tested by 
progressively excluding the stronger variables associated with outcome in univariable 
analysis. Kaplan-Meier curves with the log-rank statistic were used to illustrate outcome. 
Analyses were performed using SPSS and Stata software, and a 2-sided P value < 0.05 
was considered statistically significant. 
 
Results 
Patient characteristics 
Data for the overall population studied (n=1190) are shown in table 1, of which 979 
patients (82 %) had evidence of cardiac dysfunction and were considered to have heart 
failure, whilst 211 (18%) fulfilled neither imaging nor biomarker criteria for cardiac 
dysfunction and were considered not to have heart failure. 
 
The proportion of patients with or without heart failure taking loop diuretics was 71% 
and 37% respectively. Patients with heart failure taking loop diuretics had more evidence 
of congestion, especially those on higher doses. Patients taking higher doses of loop 
diuretics were also older, more likely to have diabetes, had worse renal function and 
lower blood pressure, haemoglobin and serum sodium concentrations. They also had 
lower left ventricular ejection fraction, larger left atrial volumes, worse right ventricular 
systolic function, higher systolic pulmonary pressure and greater IVC diameter (Table 
1).  
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For patients who did not fulfil criteria for heart failure whose plasma NTproBNP was 
125-400 ng/l, those who were taking loop diuretics had more symptoms and signs of 
congestion, worse renal function and higher heart rate compared to those who were not 
taking loop diuretics, but there were no differences in cardiac structure and function on 
echocardiography (Table 1 supplementary). 
 
Amongst patients with NTproBNP <125 ng/l, those on loop diuretics were more likely 
to have IHD, had more symptoms and slightly higher natriuretic peptides than those who 
were not taking loop diuretics but no echocardiographic differences were observed. 
 
Loop diuretics and outcome 
The entire cohort was followed up for a median of 934 (IQR: 513 – 1425) days. There 
were 450 events (205 individuals were admitted to hospital with heart failure and 245 
died). There was a dose-response relation between daily dose of diuretic and outcome. 
Compared to patients with HF not taking loop diuretics, those treated with higher doses 
of loop diuretics (>80 mg furosemide per day or equivalent) had a markedly greater risk 
of an adverse event (HR: 3.50, 95% CI: 2.49-4.93) (Kaplan-Meier curve, Figure 1).  
 
The relationship between loop diuretic use and outcome persisted in patients with heart 
failure with LVEF below and above 50% (Figure 2 and 3). 
 
Increasing clinical, echocardiographic or biochemical evidence of congestion were the 
major predictors of adverse outcome in patients with HF, rather than increasing doses of 
diuretics. For patients with heart failure who were not congested, the 1-year outcome was 
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similar regardless of the amount of loop diuretic prescribed, whilst those patients with 
more evidence of congestion had a worse outcome for any given dose of diuretic. Patients 
with more severe congestion despite higher doses of loop diuretic agents had the worst 
outcome (table 2). 
 
In univariable Cox regression analysis (Table 3), clinical, biochemical and 
echocardiographic measures of congestion, as well as diuretic dose, predicted adverse 
outcome. 
 
In multivariable analysis, increases in all three indices of congestion (clinical score, IVC 
diameter and NT-proBNP) were independent predictors of a worse prognosis (Table 3). 
By contrast, diuretic dose was not independently associated with outcome and it is only 
when the six most powerful predictors are removed from the multivariable analysis that 
dose of diuretic enters the model (table 4).   
 
 
Discussion 
Prescription of diuretics remains, to a large extent, subjective, relatively evidence-free 
and therefore a focus for opinion-based medicine (11). There is a strong relationship 
between use and dose of loop diuretics and prognosis in patients with chronic heart failure 
with either reduced or normal LVEF, but this appears to reflect their association with the 
severity of congestion whether assessed clinically, by echocardiography, or using 
natriuretic peptides. Once adjusted for the severity of congestion, the dose of diuretic 
taken does not predict outcome. However, diuretic dose can usually be readily obtained 
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from the patients record and is therefore a practical method of identifying patients at 
greater risk of an adverse outcome in surveys, audits and trials.  
 
Current guidelines emphasize that diuretics are a treatment for the clinical symptoms and 
signs of congestion and that there is no evidence of a favourable effect on disease 
progression. There are theoretical concerns that, whilst relieving congestion, diuretics 
may cause neuro-endocrine (NE) activation and accelerate disease progression but there 
is no conclusive evidence that this was ever true; introduction of NE antagonists may 
have reversed any adverse consequence of diuresis that once existed, especially the risk 
of hypokalaemia. Relief of congestion may reduce atrial and RV volumes and pulmonary 
artery pressure (19). There is evidence that the severity of RV rather than LV dysfunction 
is more tightly linked to prognosis (3, 5) and increased atrial pressure and volume may 
provoke AF (17). Therefore, diuresis, protected by agents that block NE activation and 
hypokalaemia, could have favourable effects on disease progression. 
 
The effects of diuretics on renal function are complex (20). In patients with severe 
oedema, diuretics may reduce renal parenchymal oedema and renal venous pressure 
without reducing renal arterial perfusion pressure, leading to improved renal function. In 
patients with less grossly elevated venous pressure, the fall in renal arterial perfusion 
pressure and complex changes in adenosine, intra-renal haemodynamics and tubulo-
glomerular feedback conspire to cause a decline in glomerular filtration rate. Moreover, 
washout of the medullary concentration gradient and other ‘braking’ effects may lead to 
varying degree of tolerance to diuretic effects.  
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Loop diuretics reduce congestion, but, no randomised prospective study has evaluated 
their impact on the outcome of patients with chronic heart failure, although a meta-
analysis that included 3 small trials enrolling 202 patients in total, suggested that mortality 
might be lower for those patients treated with diuretics compared to placebo (21). Given 
the need to use diuretics to control symptoms of congestion, the low event rates in patients 
with cardiac dysfunction who do not have congestion and the possibility that diuretics are 
only safe and effective in patients who have congestion, it is difficult to design definitive 
outcome studies to address this topic. Clearly, for patients with severe congestion about 
to die of fluid overload, diuretics must be life-saving.  
 
Retrospective analyses of several RCTs have raised concerns about a possible detrimental 
effect of long-term loop diuretic therapy.  In the Prospective Randomized Amlodipine 
Survival Evaluation (PRAISE) trial (13), the use of furosemide >80mg/day (or equivalent 
dose of other diuretics) or the use of metolazone combined with a loop diuretic, were 
independent predictors or mortality. In a sub-analysis of the Studies of Left Ventricular 
Dysfunction (SOLVD) (12), amongst >6000 patients with moderate or severe left 
ventricular dysfunction the risk of hospitalization or death due to worsening HF in 
patients taking non-potassium sparing diuretics (PSD) alone was greater (risk ratio [RR] 
1.31, 95% CI 1.09 to 1.57; p=0.0004) when compared to those not taking any diuretic. 
An adverse outcome with the use of more intense diuretic treatment was also observed 
by Eshaghian and colleagues (14), who also noted that those who were prescribed higher 
doses of diuretics (>160 mg of furosemide) had more severe symptoms, lower LV 
ejection fraction and cardiac index, and higher pulmonary capillary wedge pressure than 
those not taking, or taking lower doses of loop diuretics. Similar to our results, those 
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taking >160 mg furosemide had an almost 4-fold increased risk of death compared to 
those taking furosemide 0-40 mg/day.  
 
The relationship between diuretic dose and severity of congestion deserves further 
consideration. In one sense, this can be considered treatment failure, since diuretics are 
being used in an attempt to control congestion but may fail to do so adequately. This may 
reflect over-cautious use. Alternatively, it could reflect a deleterious effect of diuretics 
leading to acceleration of disease. More aggressive treatment with higher doses of loop 
diuretics might have reduced congestion but may have aggravated renal dysfunction with 
uncertain effects on symptoms and prognosis. There is perhaps more evidence addressing 
this question than is immediately apparent. A series of RCTs have investigated whether 
treatment guided by natriuretic peptides, a biomarker of congestion, improves outcomes. 
The results of these studies have been inconclusive, but often because the treatment 
strategy failed to reduce natriuretic peptides (22, 23). In some successful studies, the key 
intervention that reduced NP was diuretics (24, 25). Implanted haemodynamic monitoring 
devices also suggest that appropriate intensification of diuretic doses improves well-being 
and outcome (26). Thus, one interpretation of these trials is that treating congestion with 
higher doses of diuretics improves outcome.   
 
Despite the general belief that achieving the lowest tolerated dose, or even withdrawal of 
loop diuretics, might be beneficial for patients with heart failure, our study suggests that 
it might not be appropriate to discontinue loop diuretics once congestion is relieved, since 
congestion rather than diuretic dose was more strongly linked to outcome. Many patients 
diagnosed with heart failure, some probably erroneously, can tolerate prolonged 
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withdrawal of diuretic therapy but it is not clear whether this improves symptoms or 
outcome and does put patients at increased risk of decompensation (27, 28).  On the other 
hand, treating patients without overt clinical evidence of congestion with loop diuretics 
cannot improve symptoms but may cause NE activation (29).  
Loop diuretics are commonly prescribed for breathlessness or oedema in the absence of 
evidence of substantial cardiac dysfunction. Such patients in our study had an adverse 
outcome compared to those not taking loop diuretics, although this might reflect the 
higher prevalence of comorbidities, such as ischaemic heart disease. Alternatively, 
diuretics may have reduced plasma concentrations of NT-proBNP and masked evidence 
of cardiac dysfunction. Although diuretics might be discontinued in many of these 
patients, further trials to demonstrate the safety and tolerability of diuretic withdrawal are 
needed.   
 
Limitations 
There is no universally accepted definition of heart failure. Of patients with LVEF <50%, 
36 (5%) had an NT-proBNP <125ng/L and some might consider these patients did not 
have heart failure. Many would not accept elevation of NT-proBNP alone as diagnostic 
of heart failure. Of patients with an NT-proBNP >400ng/L and LVEF >50%, 166 (60%) 
were in AF, 22 (8%) had eGFR <30ml/minute, 67 (25%) had a normal LA volume 
(LAVI<34 mL/m2 (18)) and 181 (68%) were taking loop diuretics. Thus, very few 
patients with NT-proBNP >400ng/L had no other evidence of major cardiac dysfunction. 
On the other hand, loop diuretics may have concealed underlying cardiac dysfunction, 
normalizing NT-proBNP and atrial volumes. Withdrawal of diuretics would likely have 
revealed evidence of cardiac dysfunction in some. 
Conclusions 
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The presence of congestion assessed either clinically, by echocardiography or by plasma 
concentrations of natriuretic peptides, identifies patients with chronic heart failure at high 
risk of an adverse outcome whether or not they are taking loop diuretics. Diuretics are 
more likely to be a marker of, rather than a cause of, a worse prognosis in patients with 
heart failure receiving contemporary therapy with NE antagonists that prevent 
hypokalaemia.    
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Legend to figures 
Figure 1. Kaplan Meier curve for the primary outcome of death from all causes and 
heart failure hospitalizations in the overall population. Compared to patients with 
heart failure not taking loop diuretics, those treated with higher doses of loop diuretics 
(>80 mg furosemide per day) had a markedly greater risk of an adverse event (HR: 
3.50, 95% CI: 2.49-4.93, p<0.001). 
 
Figure 2. Kaplan Meier curve for the primary outcome of death from all causes and 
heart failure hospitalizations in patients with HF and reduced left ventricular ejection 
fraction (LVEF<50%). Compared to patients not taking loop diuretics, those treated 
with any dose of loop diuretic had a 2-fold increased risk of an adverse event (HR: 
2.18, 95% CI: 1.62-2.95, p<0.001). The risk increased with increasing dose of loop 
diuretic taken (Dose > 40 mg/day vs no diuretic: HR: 2.95, 95% CI: 2.13-4.10, 
p<0.001; Dose=10- 40 mg/day vs no diuretic: HR: 1.76, 95% CI: 1.27-2.43, p=0.001). 
 
Figure 3. Kaplan Meier curve for the primary outcome of death from all causes and 
heart failure hospitalizations in patients with raised NTproBNP (>400 ng/l) and 
normal LVEF (>50%). Compared to patients not taking loop diuretics, those treated 
with any dose of loop diuretic had a 3-fold increased risk of an adverse event (HR: 
3.04, 95% CI: 1.83-5.04, p<0.001). 
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loop diuretic had a 2-fold increased risk of an adverse event (HR: 2.18, 95% CI: 1.62-2.95, 
p<0.001). The risk increased with increasing dose of loop diuretic taken (Dose > 40 mg/day 
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Figure 3: Kaplan Meier curve for the primary outcome of death from all causes and 
heart failure hospitalizations in patients with raised NTproBNP (>400 ng/l) and 
normal LVEF (>50%). Compared to patients not taking loop diuretics, those treated 
with any dose of loop diuretic had a 3-fold increased risk of an adverse event (HR: 
3.04, 95% CI: 1.83-5.04, p<0.001). 
 
Variable Missing  No HF 
NTproBNP < 125  
ng/l 
No HF  
125<NTproBNP<400  
ng/l 
HF  
 no loop 
diuretics 
HF  
10 to 40 mg 
Furosemide 
HF  
>40 to 80 mg 
Furosemide 
HF  
> 80 
Furosemide 
 
P between 
HF groups 
Patients – no. NA 102 109 283 411 177 108 NA 
Demographic 
Age - years 0 65 (51-71) 72 (66-79) 73 (64-80) 75 (69-81) 75 (67-81) 77 (67-82) 0.013 
Sex (male) – no. (%) 0 62 (61) 61 (56) 209 (74) 279 (68) 126 (76) 82 (76) 0.227 
IHD – no. (%) 0 23 (22) 40 (36) 176 (62) 257 (63) 109 (62) 81 (75) 0.078 
DM– no. (%) 0 39 (38) 44 (40) 67 (24) 115 (28) 69 (39) 50 (46) <0.001 
HTN– no. (%) 0 65 (64) 84 (77) 170 (60) 216 (53) 85 (48) 50 (46) 0.024 
COPD– no. (%) 0 12 (12) 17 (16) 21 (7) 47 (11) 24 (14) 15 (14) 0.116 
NYHA class I– no. (%) 
NYHA class II– no. (%) 
NYHA class III– no. (%) 
 
0 
61 (60) 46 (42) 87 (31) 63 (15) 14 (8) 3 (3)  
<0.001 30 (29) 34 (31) 150 (53) 208 (51) 95 (54) 37 (34) 
11( 11) 29 (27) 46 (16) 140 (34) 68 (38) 68 (63) 
Congested– no. (%) 0 7 (7) 9 (8) 17 (6) 60 (15) 34 (19) 37 (34) <0.001 
AF– no. (%) 0 1 (1) 8 (7) 81 (29) 150 (37) 74 (41) 59 (55) <0.001 
BMI- kg/m2 0 30.6 (5.6) 32.1 (6.9) 28.7 (5.3) 28.3 (5.8) 29.5 (6.2) 29.6 (6.0) 0.198 
SBP – mmHg 0 136 (20) 140 (22) 135 (24) 129 (24) 121 (23) 124 (25) <0.001 
HR- bpm 0 73 (13) 71 (14) 70 (14) 71 (15) 73 (13) 72 (14) 0.159 
Blood results  
Haemoglobin - g/dl 1 14.1 (1.4) 13.5 (1.5) 13.7 (1.6) 13.1 (1.7) 12.9 (1.7) 12.6 (1.9) <0.001 
Creatinine - umol/l 0 79 (65-93) 90 (74-110) 90 (79-109) 105 (87-141) 113 (92-143) 131 (100-180) <0.001 
eGFR– ml/min/1.73m2 0 86 (71-108) 72 (56-90) 72 (58-85) 59 (42-75) 55 (41-71) 46 (31-64) <0.001 
Na – mmol/l 0 139 (2) 138 (3) 138 (3) 138 (3) 138 (3) 137 (4) 0.005 
K – mmol/l 5 4.2 (0.4) 4.4 (0.4) 4.4 (0.4) 4.4 (0.5) 4.4 (0.5) 4.3 (0.5) 0.241 
NTproBNP– ng/l 2 51 (29-85) 236 (161-291) 794 (381-1596) 1310 (628-2939) 1717 (735-3120) 1966 (1120-4572) <0.001 
Urea – mmol/l 0 4.8 (3.9 – 5.8) 6.4 (4.7-7.8) 5.8(4.6-7.2) 7.8 (5.9-10.30) 8.8 (6.4-11.8) 11.7 (8.3-16.1) <0.001 
Albumin – g/l 1 40 (3) 39 (3) 39 (3) 38 (3) 38 (3) 37 (4) <0.001 
Bilirubin– umol/l 0 12 (10-15) 13 (11-15) 14 (12-18) 14 (12-18) 15 (12-19) 16 (12-22) 0.028 
Treatment 
Beta-blockers– no. (%) 0 32 (31) 58 (53) 222 (78) 332 (81) 151 (85) 82 (76) 0.187 
 Table 1: Characteristics of patients by diagnosis and by amount of loop diuretic taken (only for those with HF). List of abbreviation used: IHD - 
Ischemic Heart Disease; DM – Diabetes Mellitus; COPD - Chronic Obstructive Pulmonary Disease; HTN: hypertension; SBP - Systolic Blood 
Pressure; HR: heart rate; BMI - Body Mass Index; eGFR - estimated Glomerular Filtration Rate; AF: atrial fibrillation; NTproBNP –N-terminal 
B-type natriuretic peptide; LVEDV - Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection Fraction; LAVI - Left Atrial 
Volume Index; TAPSE - Tricuspid Annular Plane Systolic Excursion; TR gradient- Trans-Tricuspid systolic gradient; IVC: inferior vena cava, 
HF: heart failure; AA: aldosterone antagonist; ACE-I: angiotensin-converting-enzyme inhibitor; ARB: Angiotensin II receptor blockers, NA: not 
applicable. *NTproBNP<125 vs 125-400. 
ACE-I or ARB– no. (%) 0 58 (57) 81 (74) 230 (81) 359 (87) 163 (92) 92 (85) 0.009 
AA– no. (%) 0 14 (14) 17 (16) 59 (21) 148 (36) 98 (55) 61 (56) <0.001 
Loop– no. (%) 0 28 (27) 50 (46) NA NA NA NA 0.006* 
Loop > 40 mg/day– no. (%) 0 3 (3) 17 (16) NA NA NA NA <0.001* 
Bendroflumethiazide– no. (%) 0 NA NA 34 (13) 2 (1) 1 (1) 2 (2) <0.001 
Metolazone– no. (%) 0 NA NA 0 0 3 (2) 3 (3) 0.001 
Echocardiography 
LVEDV – ml 0 100 (78-114) 90 (68-114) 137 (100-178) 158 (111-202) 153 (110-198) 146 (109-197) 0.001 
LVEF - % 0 59 (55-53) 59 (55-64) 45 (36-54) 40 (32-51) 40 (31-50) 42 (30-55) 0.003 
LVEF<40% 0 NA NA 111 (39) 206 (50) 89 (50) 50 (46) 0.027 
LAVI - ml/m2 0 23 (20-27) 28 (21-35) 37 (29-51) 43 (32-56) 43 (33-58) 51 (37-65) <0.001 
TAPSE – mm 2 22 (19-25) 21 (17-24) 20 (16-22) 18 (15-21) 17 (14-20) 16 (13-20) <0.001 
TR gradient – mmHg 39 17 (16-21) 20 (16-25) 25 (20-31) 25 (20-33) 26 (20-37) 31 (22-40) <0.001 
IVC – mm 38 15 (14-17) 15 (14-17) 18 (16-21) 19 (16-23) 19 (17-23) 22 (18-26) <0.001 
E/e’  735 7 (6-9) 9 (7-11) 10 (9-14) 12 (10-17) 13 (9-17) 15 (10-19) 0.002 
Events 
Deaths– no. (%) NA 6 (6) 21 (19) 45 (16) 135 (33) 66 (37) 50 (46) NA 
HF Hospitalizations– no. (%) NA 5 (5) 11 (10) 34 (12) 81 (20) 50 (28) 24 (22) NA 
1-year event free 
survival 
  
No loop 
 
Lower dose loop 
(<40 mg) 
 
Higher dose loop 
(>40 mg) 
 
 
p@ 
Clinical congestion 
Not congested (0) 92% 87% 85% 0.123 
Mild congestion (1-2) 90% 84% 76% 0.062 
Great congestion (>3) 73% 71% 54% 0.109 
P#  0.054 0.009 <0.001  
Biochemical* 
Not congested (NTproBNP<125 ng/l) 100% 100% 100% 1 
Mild congestion (125-400 ng/l) 98% 93% 100% 0.267 
Great congestion (NTproBNP > 400) 88% 82% 72% <0.001 
P#  0.025 0.066 0.009  
Biochemical** 
NTproBNP tercile 1 98% 95% 90% 0.048 
NTproBNP tercile 2 91% 87% 72% 0.001 
NTproBNP tercile 3 83% 70% 61% 0.005 
P#  0.002 <0.001 <0.001  
Echocardiographic*** 
No congestion (IVC < 16 mm) 95% 92 % 88% 0.342 
Mild congestion (IVC 17-20 mm) 92 % 92 % 83% 0.101 
Great congestion (IVC > 21 mm) 82 % 71% 61% 0.006 
P#  0.030 <0.001 <0.001  
965 patients with HF were followed-up for at least 365 days unless censored due to an event. During the first 365 days 163 events were recorded. Event 
free survival is reported. NTproBNP was not available for two patients, for 34 patients IVC diameter was not available. P for significance amongst groups of 
patients treated with increasing dose of diuretics (@) or by increasing clinical, biochemical or echocardiographic congestion (#, highlighted in bold) are 
reported. 
 
*Median NTproBNP per group:  No Loop 1107 (692-1911) ng/l; Lower dose loop: 1526 (857-3325) ng/l; Higher dose loop: 1962 (1133-3924) ng/l; p<0.001. 
**Median NTproBNP per group: Tercile 1: No Loop 224 (143-378)ng/l; Lower dose loop: 445 (237-632)ng/l; Higher dose loop: 586 (381-846)ng/l, p<0.001; 
Tercile 2: No Loop 790 (613-1021)ng/l; Lower dose loop: 1289 (1088-1623)ng/l; Higher dose loop: 1869 (1503-2129)ng/l, p<0.001; Tercile 3: No Loop 2012 
(1573-3266)ng/l; Lower dose loop: 4020 (2926-6342)ng/l; Higher dose loop: 4837 (3556-8487)ng/l, p<0.001. 
***Median NTproBNP per group:  No Loop 1736 (997-3267) ng/l; Lower dose loop: 2877 (1471-4890) ng/l; Higher dose loop: 2917 (1663-5506) ng/l; 
p<0.001; Median IVC per group:  No Loop 23 (22-24) mm; Lower dose loop: 24 (22-27) mm; Higher dose loop: 24 (22-27) mm; p=0.001. 
 
  
Variables 
 
Univariable analysis 
 
Multivariable analysis 
 HR (95% CI) χ2 p-value HR (95% CI) χ2 p-value 
Age - years 1.04 (1.03-1.05) 73.78 <0.001 1.03 (1.01-1.04) 14.88 <0.001 
Sex (men) 0.96 (0.77-1.18) 0.16 0.69    
IHD(yes vs no) 1.10 (0.90-1.35) 0.95 0.33    
DM (yes vs no) 1.07 (0.87-1.31) 0.38 0.54    
HTN(yes vs no) 0.91 (0.75-1.10) 0.95 0.33    
COPD(yes vs no) 1.11 (0.83-1.49) 0.48 0.48    
NYHA class III vs I/II 2.22 (1.83-2.70) 64.94 <0.001 1.52 (1.21-1.92) 12.99 <0.001 
Congested (yes vs no) 2.34 (1.86-2.96) 51.55 <0.001 1.38 (1.01-1.86) 4.20 0.04 
AF (yes vs no) 1.32 (1.08-1.60) 7.51 0.006    
BMI - kg/m2 0.96 (0.94-0.98) 19.31 <0.001    
SBP- mmHg 0.99 (0.99-1.00) 4.19 0.041    
HR- bpm 1.01 (1.00-1.01) 3.82 0.051    
Haemoglobin - g/dl 0.81 (0.76-0.85) 57.95 <0.001    
Creatinine - umol/l 1.01 (1.00-1.01) 69.97 <0.001    
eGFR-  ml/min/1.73m2 0.98 (0.97-0.99) 63.72 <0.001    
Na– mmol/l 0.92 (0.90-0.95) 26.36 <0.001 0.95 (0.92-0.98) 9.76 0.002 
K– mmol/l 1.27 (1.03-1.58) 4.99 0.026    
LogNTproBNP 3.87 (3.18-4.72) 181.65 <0.001 1.58 (1.15-2.17) 7.93 0.005 
Urea- mmol/l 1.09 (1.08-1.11) 127.50 <0.001 1.06 (1.03-1.09) 12.71 <0.001 
Albumin – g/l 0.91 (0.88-0.93) 44.88 <0.001    
Bilirubin– umol/l 1.03 (1.01-1.04) 13.32 <0.001    
Loop (> 80 vs < 80) 1.96 (1.50-2.55) 24.14 <0.001    
 
 
 
 
 
 
 
 
 
 
Table 3:  Univariable and multivariable Cox regression models for the composite endpoint of death or HF hospitalization in patients with HF. 
The independent predictors of adverse outcome are highlighted in bold. List of abbreviation used: IHD - Ischemic Heart Disease; DM – Diabetes 
Mellitus; COPD - Chronic Obstructive Pulmonary Disease; HTN: hypertension; SBP - Systolic Blood Pressure; HR: heart rate; BMI - Body 
Mass Index; eGFR - estimated Glomerular Filtration Rate; AF: atrial fibrillation; NTproBNP –N-terminal B-type natriuretic peptide; LVEDV - 
Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection Fraction; LAVI - Left Atrial Volume Index; TAPSE - Tricuspid 
Annular Plane Systolic Excursion; TR gradient- Trans-Tricuspid systolic gradient; IVC: inferior vena cava. 
 
 
LVEDV- ml 1.01 (1.00-1.01) 10.22 0.001    
LVEF- % 0.99 (0.98-1.00) 9.19 0.002    
LAVI - ml/m2 1.02 (1.01-1.02) 76.33 <0.001    
TAPSE – mm 0.93 (0.91-0.95) 46.48 <0.001    
TR gradient – mmHg 1.03 (1.03-1.04) 90.36 <0.001    
IVC – mm 1.11 (1.10-1.11) 138.92 <0.001 1.06 (1.03-1.09) 15.15 <0.001 
Table 4 – Different multivariable models were tested. All the variables on the left column have been included, and then we consecutively 
excluded the strongest variable(s) in the univariable analysis (those excluded are reported above each column from each model). X identifies 
variables that entered the multivariable models tested with a P<0.05. List of abbreviation used: SBP - Systolic Blood Pressure; BMI - Body Mass 
Index; eGFR - estimated Glomerular Filtration Rate; HR: heart rate; AF: atrial fibrillation; NTproBNP –N-terminal B-type natriuretic peptide; 
Variable LogNTproBNP 
removed 
LogNTproBNP 
& IVC  
removed 
LogNTproBNP 
& IVC & Urea  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad & 
LAVI  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad & 
LAVI & 
Creatinine  
removed 
LogNTproBNP 
& IVC & Urea 
& TR grad & 
LAVI & 
Creatinine & 
Congested  
removed 
Age - years X X X X X X X 
NYHA class III vs I/II X X X X X X X 
Congested – yes vs not X       
AF– yes vs not        
BMI- kg/m2        
SBP - mmHg        
HR- bpm         
Haemoglobin - g/dl      X X 
Creatinine- umol/l   X     
Na– mmol/l X X X X X X X 
K– mmol/l        
Urea- mmol/l X X      
Albumin – g/l    X X X X 
Bilirubin– umol/l     X X X 
Loop > 80 vs < 80      X X 
LVEDV- ml     X X X 
LVEF- %        
LAVI- ml/m2  X X X    
TAPSE– mm    X X X X 
TR gradient– mmHg X X X     
IVC– mm X       
LVEDV - Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection Fraction; LAVI - Left Atrial Volume Index; TAPSE - 
Tricuspid Annular Plane Systolic Excursion; TR gradient- Trans-Tricuspid systolic gradient; IVC: inferior vena cava. 
 
